NTA (Neuroscience Trials Australia) is an Australian-owned, niche contract research organization (CRO) specializing in neuroscience clinical research and beyond. NTA supports pharmaceutical, biotechnology, cell therapy and device companies to undertake their phase I-IV clinical trials according to global regulatory standards, including the TGA, FDA and EMA. Our therapeutic areas of expertise include epilepsy, stroke and stroke-related conditions, multiple sclerosis, Alzheimer’s, dementia, psychotic disorders, Parkinson’s, brain and spinal cord injury, Huntington’s, neurosurgery, pain, mental health, neuromuscular diseases and migraine. NTA partners with The Florey Institute of Neuroscience and Mental Health, the largest brain research institute in the southern hemisphere, which facilitates a unique professional network. NTA has direct access to therapeutic disease specialists, key opinion leaders and clinical trial sites that collectively enable us to deliver quality clinical trial services with strong recruitment outcomes. Although NTA mainly works in the neuroscience space, we are increasingly supporting our client’s portfolios in other therapeutic indications including oncology, immunology, ophthalmology, endocrinology and infectious diseases.